Navigation Links
FDA Approved Treatment for Painful Intercourse (Dyspareunia) Due to Menopause
Date:2/27/2013

ed, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.

Breast Cancer: Osphena has not been adequately studied in women with breast cancer; therefore Osphena should not be used in women with known or suspected breast cancer or with a history of breast cancer.

Severe Hepatic Impairment: Do not use Osphena in women with severe hepatic impairment as it has not been studied.

Adverse Reactions: In clinical studies, the more commonly reported adverse reactions (greater than or equal to 1 percent) in patients treated with Osphena 60 mg compared to placebo were: hot flush (7.5 percent vs. 2.6 percent), vaginal discharge (3.8 percent vs. 0.3 percent), muscle spasms (3.2 percent vs. 0.9 percent), hyperhidrosis (1.6 percent vs. 0.6 percent), and genital discharge (1.3 percent vs. 0.1 percent).

Drug Interactions

  •     Do not use estrogens or estrogen agonists/antagonists or fluconazole concomitantly with Osphena.
  •     Moderate to Strong CYP3A4 inhibitors (e.g., ketoconazole, fluconazole) will increase Osphena (ospemifene) drug concentrations while moderate to strong CYP3A4, CYP2C9, or CYP2C19 inducers (e.g. rifampin) will decrease Osphena (ospemifene) drug concentrations.
  •     Coadministration of Osphena with drugs that inhibit CYP3A4 and CYP2C9 may increase the risk of Osphena related adverse reactions.
  •     Osphena had no effect on the pharmacokinetics of a single 10 mg dose of warfarin. The effect of Osphena on International Normalized Ration (INR) or prothrombin time (PT) was not studied.
  •     Osphena (ospemifene) is highly protein bound. Use cautiously with highly protein bound drugs as use with other highly protein-bound drugs may lead to increase exp
    '/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. ASHA Approved Continuing Education Provider HomeCEUConnection.com Announces Two New Live, Interactive Webinars for California Speech-Language Pathologists.
2. EzW2Correction Software Was Approved By SSA To Print W-2C and W-3C On White Paper
3. Newly approved oral medication slows rheumatoid arthritis joint damage
4. Westbridge Agricultural Products Announces that Botector® has been EPA Approved as an Organic Biopesticide to Prevent Gray Mold in Grapes
5. First FDA approved subcutaneous implantable defibrillator available for patients
6. Not all lung cancer patients who could benefit from crizotinib are identified by FDA-approved test
7. Moffitt Cancer Center melanoma expert reviews unique adverse events with newly approved drug
8. AGA releases first independently developed ABIM-approved Practice Improvement Module in GI
9. Mayo Clinic offers newly approved treatment for acid reflux disease
10. Experimental Vitiligo Treatment Shows Promise in Mice
11. DNDi receives BBVA Foundation award for delivering new treatments for neglected diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 2015 CALNOC, the nation’s first nursing ... RN, FAAN, will keynote their upcoming conference – Navigating ... CA on October 26, 2015. , Dr. Burnes ... of Nurse Executives (AONE) and the first African American ... American Academy of Nursing and the National Black Nurses ...
(Date:4/21/2015)... VA (PRWEB) April 21, 2015 The Science ... as a special addition to its Lunch Break Science program. ... World of Quarks! – taking guests from the subatomic world ... form. , The Museum invites members of the community to ... the Jefferson Lab physicist. Guests will delve into the nucleus ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 Renewable energy, ... a few of the Earth Day topics USM ... and national leaders debate the affect of climate change ... variety of subject matter touching on the environmental concerns ... segments will delve into sustainable lifestyles, clean air options, ...
(Date:4/21/2015)... April 21, 2015 On Saturday, May ... the rest of his team from Georgia Eye ... to End Lupus Now, being held in Piedmont Park ... Walk proved to be the largest LFA-sponsored walk in ... effort to raise funds and awareness for lupus, an ...
(Date:4/21/2015)... 21, 2015 Invictus Medical has ... Illinois university for a second innovative technology aimed ... conducive to newborn infants’ cognitive development. , “This ... problems we have identified through extensive interviews and ... George Hutchinson, Invictus Medical’s Chief Technology Officer. “We ...
Breaking Medicine News(10 mins):Health News:Nationally Recognized Nurse Leader Linda Burnes Bolton to Present Keynote Address at CALNOC Conference 2Health News:Quarks and Forks at the Science Museum of Virginia 2Health News:USM Studios’ Programming Focuses on the Environment 2Health News:9th Annual Walk to End Lupus Now 2Health News:9th Annual Walk to End Lupus Now 3Health News:Invictus Medical Secures Rights to Second Promising New NICU Technology 2
... Drug Administration is scrutinizing the claims made by a ... to the claims made by the businessman Allan Lord, he ... The Bio-Germ Protection kits contain skin lotion, a nasal spray, ... online. ,According to the company, the lotion, which is ...
... 'Transcranial Magnetic Stimulation' (TMS) maybe the way forward ... aggressive electro-shock therapy., ,Electro-Shock Therapy or ECT is ... treat severe depression for many decades. However, it can ... and requires general anesthesia. In ECT the doctors pass ...
... can prevent the spread of melanoma// and other forms of ... a chemical found in turmeric, can block a biological pathway ... The chemical in the spices inhibits a protein called nuclear ... abnormal inflammations that can lead to a number of disorders ...
... revealed that consumption of fruits, vegetables and foods high in ... risk of heart disease. ,Western cuisines are not so ... plant foods in the diet. ,10 healthy individuals were ... to each of them. The diets were a vegetarian diet ...
... be responsible for various immune deficiency syndromes, and researchers// ... two different form of immune deficiency conditions called immunoglobulin ... ,Immune deficiency syndrome may be hereditary or acquired. Hereditary ... defects in the cells and tissues that are responsible ...
... help in the brain development of foetus and infants for ... administered to pregnant women. A new study conducted by scientists ... slow down the cognitive decline in middle-aged subjects. , ... and women) with increased levels of homocysteine. This amino acid ...
Cached Medicine News:Health News:A New Product Offering protection against anthrax 2Health News:Strong Magnetic Stimulation Can Help Treating Severe Depression 2Health News:Fibre Rich Food A Boon For Lowering Cholesterol 2
(Date:4/20/2015)... 20, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... for the Phase 1 study of MM-302, a ... cancer.  The results were presented today by Patricia ... session at the 2015 American Association for Cancer ... PA. Data described the safety and ...
(Date:4/20/2015)... April 20, 2015  Sigma-Aldrich Corporation (Nasdaq: ... (CR) Magazine,s list of the 100 Best Corporate ... corporate responsibility performance.  Sigma-Aldrich ranked fifth, its highest ... the list. "We are honored to ... efforts and we are extremely pleased with our ...
(Date:4/20/2015)... April 20, 2015 The preclinical contract research organization ... of drugs and safety testing of medical devices, announces that ... this week,s workshop " Drug Transporters in ADME: From the ... . The title of Dr. Hidalgo,s talk is "Modern ... session entitled "Transporter Tools of the Future." The ...
Breaking Medicine Technology:Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 2Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 3Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 4Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 5Sigma-Aldrich Named to CR Magazine's 100 Best Corporate Citizens List 2Absorption Systems Chief Scientist Ismael Hidalgo to Present at International Workshop on Drug Transporters 2
... YORK, Oct. 7, 2011 Intellect Neurosciences, Inc. (OTCBB: ... clinical-stage pipeline, and multiple licenses with major pharmaceutical companies ... interview with Dr. Daniel Chain, Ph.D., Chairman and CEO ... Dr. Chain will be discussing the state ...
... Health Solutions, Inc. (NYSE: MHS ) today ... the Silver Award for Best Practices in Health Care ... healthcare accreditation organization, during the URAC 12th Annual Quality ... ) Medco,s program was selected as one ...
Cached Medicine Technology:Intellect Neurosciences CEO to be Featured on Wall Street Reporter 2Medco Wins 2011 URAC Award for Best Practices in Health Care Consumer Empowerment and Protection 2Medco Wins 2011 URAC Award for Best Practices in Health Care Consumer Empowerment and Protection 3